Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,628 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04351230 | T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer | withdrawn | Phase 2 | 0 | Academic and Community Cancer Research UnitedOTHER | 1 | May 26, 2022 | clinicaltrials |
| NCT03811262 | Comparison of Erector Spinae Plane Block With PECS II Block in Patients Undergoing Breast Cancer Surgery | withdrawn | N/A | 0 | University of PadovaOTHER | 1 | May 23, 2022 | clinicaltrials |
| NCT03261323 | Breast Reconstruction Following Breast Cancer in Very High Risk Patients | withdrawn | N/A | 0 | Case Comprehensive Cancer CenterOTHER | 1 | May 20, 2022 | clinicaltrials |
| NCT05041751 | Myofascial Release or Trigger Point Injections for the Reduction of Post-Mastectomy Pain Syndrome | withdrawn | N/A | 0 | M.D. Anderson Cancer CenterOTHER | 0 | May 17, 2022 | clinicaltrials |
| NCT05037019 | SIGNAL During a COVID-19 Pandemic | withdrawn | N/A | 0 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 0 | May 16, 2022 | clinicaltrials |
| NCT05359874 | Improvement of the Operative Outcome in Patients With Primary VEGF + Unifocal Breast Cancer or DCIS Through the Intraoperative Visualization of the Tumor Using Molecular Imaging and Bevacizumab-IRDye-800CW(DoT-FMI) | withdrawn | Phase 2 | 0 | Technical University of MunichOTHER | 0 | May 4, 2022 | clinicaltrials |
| NCT05156463 | The PAI Trial for Breast and Colon Cancer Survivors | withdrawn | N/A | 0 | Milton S. Hershey Medical CenterOTHER | 0 | Apr 28, 2022 | clinicaltrials |
| NCT04762901 | LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer | withdrawn | Phase 1 | 0 | Wake Forest University Health SciencesOTHER | 0 | Apr 26, 2022 | clinicaltrials |
| NCT05234606 | A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Silverback TherapeuticsINDUSTRY | 0 | Apr 12, 2022 | clinicaltrials |
| NCT02850419 | Heat-Activated Target Therapy of Local-Regional Relapse in Breast Cancer Patients(EURO-DIGNITY) | withdrawn | Phase 2 | 0 | ImunonINDUSTRY | 3 | Apr 7, 2022 | clinicaltrials |
| NCT03682744 | CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC) | withdrawn | Phase 1 | 0 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Apr 6, 2022 | clinicaltrials |
| NCT02427581 | Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy | withdrawn | Phase 1 | 0 | Washington University School of MedicineOTHER | 0 | Mar 10, 2022 | clinicaltrials |
| NCT04856475 | Evaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast Cancer(NeraBrain) | withdrawn | Phase 2 | 0 | Jules Bordet InstituteOTHER | 0 | Mar 2, 2022 | clinicaltrials |
| NCT05008510 | P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC .(VERU-111) | withdrawn | Phase 2 | 0 | Veru Inc.INDUSTRY | 0 | Feb 8, 2022 | clinicaltrials |
| NCT04691999 | The Effect of Intermittent Fasting on Body Composition in Women With Breast Cancer(EFFECT-BC) | withdrawn | N/A | 0 | Duke UniversityOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT04038489 | COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer(Breast 51) | withdrawn | Phase 2 | 0 | University of VirginiaOTHER | 1 | Nov 22, 2021 | clinicaltrials |
| NCT03511079 | Music as a Perioperative Therapy in Breast Cancer Patients | withdrawn | N/A | 0 | Milton S. Hershey Medical CenterOTHER | 1 | Nov 4, 2021 | clinicaltrials |
| NCT03634150 | Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Immune System Key LtdINDUSTRY | 1 | Oct 26, 2021 | clinicaltrials |
| NCT01714128 | FES-PET for Patients Treated on NCI Protocol 8762 | withdrawn | N/A | 0 | Washington University School of MedicineOTHER | 1 | Oct 25, 2021 | clinicaltrials |
| NCT04020523 | Advanced MR Techniques for Breast Cancer Detection(RAPIDIRM) | withdrawn | N/A | 0 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Oct 20, 2021 | clinicaltrials |
| NCT04585724 | Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases | withdrawn | Phase 1 | 0 | Emory UniversityOTHER | 0 | Oct 18, 2021 | clinicaltrials |
| NCT03940248 | Proton Accelerated Partial Breast Irradiation(APBI) | withdrawn | Phase 2 | 0 | University of CincinnatiOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT04917640 | Registry for Accelerated Partial Breast Irradiation With (SBRT) or (IMRT) | withdrawn | — | 0 | GenesisCare USAOTHER | 1 | Sep 8, 2021 | clinicaltrials |
| NCT03872505 | Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer(PANDoRA) | withdrawn | Phase 2 | 0 | Cedars-Sinai Medical CenterOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT02161679 | Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer | withdrawn | Phase 2 | 0 | Gilead SciencesINDUSTRY | 0 | Aug 19, 2021 | clinicaltrials |
| NCT04067102 | Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBC | withdrawn | N/A | 0 | Hebei Medical University Fourth HospitalOTHER | 1 | Jul 9, 2021 | clinicaltrials |
| NCT04655183 | Study of M4344 in Combination With Niraparib | withdrawn | Phase 1 / Phase 2 | 0 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 0 | Jun 30, 2021 | clinicaltrials |
| NCT04449809 | Exercise Regimen Designed to Improve Functional Mobility, Body Composition, and Strength After Breast Conservation Therapy for Women With Early Stage Breast Cancer(EXERT-BC) | withdrawn | N/A | 0 | Duke UniversityOTHER | 1 | Jun 21, 2021 | clinicaltrials |
| NCT04292860 | Reverse Axillary Mapping in Breast Radiation Treatment Planning | withdrawn | — | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 0 | May 27, 2021 | clinicaltrials |
| NCT03161834 | Plasma Circulating Tumor DNA Analyses in ER+ Metastatic Breast Cancer | withdrawn | — | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | May 21, 2021 | clinicaltrials |
| NCT04498520 | Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer | withdrawn | Phase 1 | 0 | Pamela MunsterOTHER | 0 | May 18, 2021 | clinicaltrials |
| NCT04487912 | Dynamics and Tracer Distribution of Tilmanocept in Early Stage Breast Cancer | withdrawn | Phase 4 | 0 | University Hospital, GhentOTHER | 1 | May 14, 2021 | clinicaltrials |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | withdrawn | Phase 1 / Phase 2 | 0 | NKGen Biotech, Inc.INDUSTRY | 0 | May 12, 2021 | clinicaltrials |
| NCT03658213 | To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer.(LARES) | withdrawn | Phase 3 | 0 | AstraZenecaINDUSTRY | 1 | May 10, 2021 | clinicaltrials |
| NCT02038699 | A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Jazz PharmaceuticalsINDUSTRY | 1 | Apr 30, 2021 | clinicaltrials |
| NCT04828044 | Microwave Ablation of Breast Tumors | withdrawn | — | 0 | St. Joseph Hospital of OrangeOTHER | 1 | Apr 1, 2021 | clinicaltrials |
| NCT03437915 | BrUOG 351: PRE-OPERATIVE APBI USING NIBB(351) | withdrawn | N/A | 0 | Jaroslaw HepelOTHER | 0 | Mar 9, 2021 | clinicaltrials |
| NCT03863301 | MRI-guided Single Dose Preoperative Radiotherapy in Low-risk Breast Cancer(ABLATIVE-2) | withdrawn | Phase 2 | 0 | UMC UtrechtOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT04281355 | Individualized Locoregional Treatment of Initially Biopsy-proven Node-positive Breast Cancer After Primary Systemic Therapy(INDAX) | withdrawn | Phase 3 | 0 | Karolinska InstitutetOTHER | 0 | Feb 25, 2021 | clinicaltrials |
| NCT00397761 | Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer | withdrawn | Phase 2 / Phase 3 | 0 | Medstar Health Research InstituteOTHER | 1 | Feb 17, 2021 | clinicaltrials |
| NCT02336984 | A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS | withdrawn | Phase 1 / Phase 2 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 11, 2021 | clinicaltrials |
| NCT03563352 | Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer | withdrawn | — | 0 | University of Southern CaliforniaOTHER | 1 | Dec 14, 2020 | clinicaltrials |
| NCT03295695 | PET-CT Imaging Using FDG-labeled Human Erythrocytes in Breast Cancer Patient | withdrawn | Early Phase 1 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT03159598 | Drain-Less Abdominally Based Breast Reconstruction Using Lysine-Derived Urethane Adhesive | withdrawn | N/A | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Nov 24, 2020 | clinicaltrials |
| NCT04142554 | Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer(LCCC1820) | withdrawn | Phase 1 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 0 | Nov 3, 2020 | clinicaltrials |
| NCT03846583 | Tucatinib + Abemaciclib + Herceptin for HER2+ MBC | withdrawn | Phase 1 | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Oct 23, 2020 | clinicaltrials |
| NCT03524261 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Breast Cancer | withdrawn | Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT04220476 | CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer(CIMER) | withdrawn | Phase 2 | 0 | Weill Medical College of Cornell UniversityOTHER | 0 | Sep 21, 2020 | clinicaltrials |
| NCT02822196 | Serratus Anterior Muscle Plane Block vsThoracic Paravertebral Block For Unilateral Mastectomies | withdrawn | Phase 4 | 0 | The University of Texas Health Science Center, HoustonOTHER | 1 | Sep 16, 2020 | clinicaltrials |
| NCT01818999 | Ixabepilone and SBRT For Metastatic Breast Cancer | withdrawn | Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 20, 2020 | clinicaltrials |
Data updated 23 days agoSource updated May 26, 2022source: clinicaltrials